Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Is there any data on the safety or efficacy of combining osimertinib-based therapy with HER2-targeted treatment in patients with EGFR-mutant NSCLC and concurrent HER2-positive breast cancer?
Related Questions
In stage IV oligometastatic NSCLC, when considering local consolidative therapies to the primary tumor, do providers typically stage the mediastinum at diagnosis or after initial systemic therapy (assuming no progression)?
Will you offer lurbinectedin with atezolizumab for patients with ES-SCLC during maintenance if they had brain metastases at baseline?
In a patient with potentially resectable lung cancer experiencing severe pain due to chest wall invasion, would you consider palliative radiation therapy prior to neoadjuvant/perioperative chemoimmunotherapy?
When, if at all, do you utilize neoadjuvant chemotherapy alone for resectable, Stage II NSCLC with mutations such as EGFR or ALK?
Would you switch from carboplatin/etoposide to cisplatin/etoposide in an LS-SCLC patient who initially declines cisplatin but subsequently agrees to it?
When should a biopsy be obtained to rule out small cell transformation in a patient with stage IV NSCLC and an EGFR mutation?
How do you typically approach adjuvant therapy for a Masaoka stage IVa thymoma post-R0 resection?
When will you choose Tarlatamab over an alternative systemic therapy (e.g. lurbinectedin, topotecan) for relapsed ES SCLC?
Is concurrent immuno-radiation therapy a viable treatment option for patients with unresectable, non-metastatic, locally advanced lung cancer, who have high PD-L1 expression and no oncogenic mutations?
How would you approach the management of a patient with Stage IV NSCLC harboring both a classical and non-classical compound EGFR mutations?
